Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- FDA Snubs Daiichi Sankyo’s Nausea Med
February 7, 2017
- ASKA to Absorb Former Actavis JV
February 7, 2017
- Sanofi, Yakult Honsha Link Arms on Zaltrap
February 7, 2017
- Ex-Lilly Exec Tsunaba Tapped as Novartis Japan Chief
February 7, 2017
- Ono Denies Nikkei Report on US Mega Acquisition Plan
February 7, 2017
- Sumitomo Dainippon Sees Blockbuster Potential for Napabucasin
February 6, 2017
- IP High Court Rules in Lilly’s Favor on Alimta Vitamin Therapy Patents
February 6, 2017
- Janssen, Mitsubishi Tanabe to Copromote Stelara for Crohn’s Disease
February 6, 2017
- Eisai to Begin Japan PIII on Fycompa Monotherapy for Partial-Onset Seizures
February 6, 2017
- Bioverativ Japan Launched on Feb. 1
February 3, 2017
- Ono’s Opdivo Sales at 82.6 Billion Yen in April-December
February 3, 2017
- Takeda Wants to Be Global GI Leader in 2025, Not in Acquisition Frenzy Mode: CEO
February 3, 2017
- Sawai, Kowa/Nissan Chemical Settle US Patent Suit over Livalo
February 3, 2017
- Nippon Shinyaku’s DMD Med Gets FDA’s Rare Pediatric Disease Designation
February 3, 2017
- Chugai to Optimize Area Management, Strengthen Expertise through Marketing System Reorganization: Marketing Chief
February 3, 2017
- Chugai to File Flurry of Applications in 2017 for New Drugs and Indications Including Emicizumab
February 3, 2017
- Chugai to Mull Authorized Biosimilars for 3 Key Cancer Meds on “Case-by-Case Basis”
February 2, 2017
- Takeda’s R&D Organization Rejig Making Steady Headway as a Whole
February 2, 2017
- New Firm for Nesp Biosimilar Will Broaden Options: Kyowa Kirin President
February 2, 2017
- EA Pharma Seeks Japan Approval of Constipation Med
February 2, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…